Related Experiment Video
Updated: Jul 4, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
A retrospective analysis for early-stage non-endometrioid endometrial cancers
Eunkyoung Lee1, Won Kyung Cho1, Won Park1
1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Purpose:
This study aimed to investigate treatment outcomes and explore optimal adjuvant treatment options for patients with early-stage uterine serous carcinoma (USC) and clear cell carcinoma (CCC).
Materials And Methods:
We retrospectively reviewed the records of 63 patients diagnosed with stage I-II (2009 International Federation of Gynecology and Obstetrics [FIGO]) USC or CCC. Survival outcomes were estimated using the Kaplan-Meier method, and comparisons between groups were performed with the log-rank test.
Results:
Among the 63 patients, 36 (57.1%) had USC and 25 (39.7%) had CCC. According to the revised 2023 FIGO staging system, 23 patients (36.5%) were stage IC, and 40 (63.5%) were stage IIC. Adjuvant treatment included no adjuvant therapy (23.8%), chemotherapy alone (39.7%), radiotherapy alone (28.6%), and combined chemotherapy plus radiotherapy (8.0%). After a median follow-up of 54 months (range, 5 to 227 months), the 5-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 89.5% and 85.7%, respectively. Patients with CCC had a 5-year PFS of 95.8% and OS of 92.3%, whereas those with USC had a 5-year PFS of 85.1% and OS of 81.4%. Most recurrences (7/63, 11.1%) were distant, occurring predominantly in USC cases (6/7) and 2023 stage IIC (7/7).
Conclusion:
In this retrospective study, early-stage USC and CCC had very favorable PFS and survival outcomes. Thus, future randomized clinical trial or large cohort study is necessary to determine the optimal adjuvant treatments in these patients.
